Literature DB >> 3965110

Prolactin cell carcinoma of the pituitary. Clinicopathologic, immunohistochemical, and ultrastructural study of a case with cranial and extracranial metastases.

B W Scheithauer, R V Randall, E R Laws, K T Kovacs, E Horvath, M D Whitaker.   

Abstract

A patient with a primary adenohypophyseal neoplasm who had a long course marked by multiple surgical resections, radiation therapy, and high-dose dopamine agonist therapy developed local invasion as well as cranial and extracranial osseous metastatic lesions. The serum prolactin levels were greatly elevated, and immunohistochemical studies demonstrated prolactin in the cytoplasm of primary and metastatic tumor cells. Ultrastructural features of lactotrophic differentiation, including misplaced granule exocytosis, were observed. This is the third reported case of prolactin cell carcinoma that metastasized despite high-dose dopamine agonist therapy. Analysis of the patient's serum prolactin showed no abnormality in the chromatographic profile of biologic activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3965110     DOI: 10.1002/1097-0142(19850201)55:3<598::aid-cncr2820550320>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

Review 1.  Malignant pituitary tumours.

Authors:  G A Kaltsas; A B Grossman
Journal:  Pituitary       Date:  1998-04       Impact factor: 4.107

2.  Aggressive giant pituitary adenoma presenting as a nasopharyngeal mass: magnetic resonance imaging and pathologic findings.

Authors:  T P Ravichandran; R Bakshi; R R Heffner; K J Gibbons; V E Bates; D J Durante; W R Kinkel
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

3.  Histochemical study of pituitary adenomas with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nucleolar organizer region counts.

Authors:  M Shibuya; F Saito; T Miwa; R L Davis; C B Wilson; T Hoshino
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

4.  Multiple intracranial recurrent tumors with hyperprolactinemia combined with a parasellar malignant fibrous histiocytoma long after transfrontal surgery and irradiation to a pituitary adenoma.

Authors:  M Fujikawa; K Okamura; K Sato; M Shiratsuchi; T Yao; T Mizokami; M Fujishima
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

5.  Non-functioning pituitary carcinoma.

Authors:  Petra Nadja Elsässer Imboden; François-Xavier Borruat; Nicolas De Tribolet; Kathleen Meagher-Villemure; Alesia Pica; Fulgencio Gomez
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

6.  Pituitary carcinoma.

Authors:  M D Cusimano; P Ohori; A J Martinez; C Jungreis; D C Wright
Journal:  Skull Base Surg       Date:  1994

Review 7.  Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).

Authors:  Nèle Lenders; Ann McCormack
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 8.  Intracranial dissemination of pituitary adenoma. Case report and review of the literature.

Authors:  M T Giordana; P Cavalla; A Allegranza; B Pollo
Journal:  Ital J Neurol Sci       Date:  1994-05

9.  An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.

Authors:  Omalkhaire M Alshaikh; Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2019-06       Impact factor: 3.943

10.  Dopaminergic resistance in a case of invasive macroprolactinoma.

Authors:  D Schwarzstein; A García-Patterson; G Giménez; J Calaf; M Puig-Domingo; A Caixàs; X Matías-Guiu; S M Webb
Journal:  J Endocrinol Invest       Date:  1993-06       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.